Cipher Pharmaceuticals IncOTCQX International:CPHRFView on Canadian Exchange
- LAST PRICE10.2500
- TODAY'S CHANGE (%)-0.3600 (-3.3930%)
- Bid / Lots9.4500/ 6
- Ask / Lots12.0000/ 1
- Open / Previous Close10.6600 / 10.6100
- Day Range
- 52 Week Range
- Volume23,600
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CPHRF |
|---|---|---|
| 09:32 ET | 190 | 10.66 |
| 09:44 ET | 200 | 10.59 |
| 09:51 ET | 300 | 10.44 |
| 09:53 ET | 3770 | 10.47 |
| 09:55 ET | 1500 | 10.458 |
| 09:57 ET | 1000 | 10.458 |
| 10:04 ET | 400 | 10.46 |
| 10:45 ET | 1429 | 10.455 |
| 10:47 ET | 2000 | 10.55 |
| 11:25 ET | 1000 | 10.51 |
| 12:19 ET | 150 | 10.42 |
| 01:27 ET | 1000 | 10.35 |
| 02:36 ET | 600 | 10.2515 |
| 02:48 ET | 2100 | 10.31 |
| 02:50 ET | 2000 | 10.41 |
| 03:51 ET | 300 | 10.25 |
Nov 11, 2024
DJ Cipher Pharmaceuticals Inc Price Target Cut to C$17.00/Share From C$19.00 by Stifel Nicolaus, from 11:58AM ET on Monday Nov 11, 2024 by Dow Jones
11:58AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
Cipher Pharmaceuticals Reports Third Quarter 2024 Results, from 6:00PM ET on Thursday Nov 07, 2024 by Dow Jones
6:00PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Cipher Pharmaceuticals Reports Third Quarter 2024 Results, from 6:00PM ET on Thursday Nov 07, 2024 by Dow Jones
6:00PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cipher Pharmaceuticals Inc | 380.4M | 16.3x | +78.01% |
Company Information
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.
Contact Information
- Headquarters
- 5750 Explorer Drive,, Suite 404MISSISSAUGA, ON, Canada L4W 0A9
- Phone
- 905-602-5840
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $380.4M |
|---|---|
Revenue (TTM) | $37.0M |
Shares Outstanding | 25.6M |
Cipher Pharmaceuticals Inc does not pay a dividend. | |
Beta | 1.13 |
EPS | $0.88 |
Book Value | $4.69 |
P/E Ratio | 16.3x |
Price/Sales (TTM) | 10.3 |
Price/Cash Flow (TTM) | 14.6x |
Operating Margin | 30.32% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
